FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379329566> ?p ?o ?g. }

• W4379329566 endingPage "1572" @default.
• W4379329566 startingPage "1572" @default.
• W4379329566 abstract "1572 Background: In addition to being required by the Federal Policy for the Protection of Human Subjects for United States-based institutions that receive federal funding and are engaged in cooperative research projects, the use of a central Institutional Review Board (cIRB) has multiple benefits. Yet more advanced trial designs have unique needs and challenges that may hinder adoption of an efficient cIRB. Platform trials, which require both a master protocol and successive individual protocol amendments for each new agent, are prone to high regulatory burden that can slow trial recruitment, representing a significant workload for study personnel. Specific challenges for platform trials include high burden of new amendments and IRB review schedules staggered across sites, making it challenging to have all sites operating under the same amendment concurrently. Methods: Administrative assessments were collected over the course of the I-SPY2 trial. The primary outcome of interest was time from amendment submission to approval (calculated as the number of days from submission to the local IRB by the site investigators to approval by the local IRB). Quantitative data in terms of hours spent on regulatory tasks pre- and post-cIRB implementation was estimated. Site investigators were asked in December 2022 to complete a brief questionnaire to investigate perceptions on changes to workload and level of comfort using a cIRB. Results: Amendments were activated when 50% of high accruing sites had IRB approval. The number of sites with approval for an amendment to go live was < 25% prior to cIRB adoption, and 83% after. Following transition to the cIRB in February 2021, the mean time from amendment submission to approval decreased from 54.4 to 20.7 days by Jan 2023. Changes to the informed consent were possible once the cIRB was adopted, including: standardizing site-specific IRB language in a section of the consent, so it need not be adjusted with every new agent amendment; standardizing site-specific workflows; shortening consent and making it more patient friendly. The average time that CRCs spent on regulatory work at each site decreased by an average of 160 minutes, but was variable, revealing continued use of local IRB, other committees at some sites. A total of 14 respondents completed the survey; most respondents indicated that keeping up with the amendment approval process was easier post-cIRB and 94% were comfortable relying on a cIRB. The short time for cIRB approval revealed the inefficiency of other processes, including coverage analysis and building of drug order sets. Conclusions: Active engagement of cIRB leadership and IRB working group has enabled regulatory review that now takes less than 30 days. The cIRB is now the standard for the I-SPY family of trials. Other services can also be shared and will continue to drive efficiency and reduce the regulatory burden for sites." @default.
• W4379329566 created "2023-06-05" @default.
• W4379329566 creator A5005007467 @default.
• W4379329566 creator A5013288976 @default.
• W4379329566 creator A5015982056 @default.
• W4379329566 creator A5016957323 @default.
• W4379329566 creator A5017154069 @default.
• W4379329566 creator A5017166707 @default.
• W4379329566 creator A5021228514 @default.
• W4379329566 creator A5029076260 @default.
• W4379329566 creator A5036018104 @default.
• W4379329566 creator A5042303150 @default.
• W4379329566 creator A5056157669 @default.
• W4379329566 creator A5063684368 @default.
• W4379329566 creator A5071176191 @default.
• W4379329566 creator A5072789687 @default.
• W4379329566 creator A5080385299 @default.
• W4379329566 creator A5085329460 @default.
• W4379329566 creator A5091848952 @default.
• W4379329566 date "2023-06-01" @default.
• W4379329566 modified "2023-10-16" @default.
• W4379329566 title "Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency." @default.
• W4379329566 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1572" @default.
• W4379329566 hasPublicationYear "2023" @default.
• W4379329566 type Work @default.
• W4379329566 citedByCount "0" @default.
• W4379329566 crossrefType "journal-article" @default.
• W4379329566 hasAuthorship W4379329566A5005007467 @default.
• W4379329566 hasAuthorship W4379329566A5013288976 @default.
• W4379329566 hasAuthorship W4379329566A5015982056 @default.
• W4379329566 hasAuthorship W4379329566A5016957323 @default.
• W4379329566 hasAuthorship W4379329566A5017154069 @default.
• W4379329566 hasAuthorship W4379329566A5017166707 @default.
• W4379329566 hasAuthorship W4379329566A5021228514 @default.
• W4379329566 hasAuthorship W4379329566A5029076260 @default.
• W4379329566 hasAuthorship W4379329566A5036018104 @default.
• W4379329566 hasAuthorship W4379329566A5042303150 @default.
• W4379329566 hasAuthorship W4379329566A5056157669 @default.
• W4379329566 hasAuthorship W4379329566A5063684368 @default.
• W4379329566 hasAuthorship W4379329566A5071176191 @default.
• W4379329566 hasAuthorship W4379329566A5072789687 @default.
• W4379329566 hasAuthorship W4379329566A5080385299 @default.
• W4379329566 hasAuthorship W4379329566A5085329460 @default.
• W4379329566 hasAuthorship W4379329566A5091848952 @default.
• W4379329566 hasConcept C111919701 @default.
• W4379329566 hasConcept C141071460 @default.
• W4379329566 hasConcept C142724271 @default.
• W4379329566 hasConcept C204787440 @default.
• W4379329566 hasConcept C2777106319 @default.
• W4379329566 hasConcept C2778476105 @default.
• W4379329566 hasConcept C2780385302 @default.
• W4379329566 hasConcept C41008148 @default.
• W4379329566 hasConcept C509550671 @default.
• W4379329566 hasConcept C535046627 @default.
• W4379329566 hasConcept C71924100 @default.
• W4379329566 hasConceptScore W4379329566C111919701 @default.
• W4379329566 hasConceptScore W4379329566C141071460 @default.
• W4379329566 hasConceptScore W4379329566C142724271 @default.
• W4379329566 hasConceptScore W4379329566C204787440 @default.
• W4379329566 hasConceptScore W4379329566C2777106319 @default.
• W4379329566 hasConceptScore W4379329566C2778476105 @default.
• W4379329566 hasConceptScore W4379329566C2780385302 @default.
• W4379329566 hasConceptScore W4379329566C41008148 @default.
• W4379329566 hasConceptScore W4379329566C509550671 @default.
• W4379329566 hasConceptScore W4379329566C535046627 @default.
• W4379329566 hasConceptScore W4379329566C71924100 @default.
• W4379329566 hasFunder F4320332161 @default.
• W4379329566 hasIssue "16_suppl" @default.
• W4379329566 hasLocation W43793295661 @default.
• W4379329566 hasOpenAccess W4379329566 @default.
• W4379329566 hasPrimaryLocation W43793295661 @default.
• W4379329566 hasRelatedWork W2037318693 @default.
• W4379329566 hasRelatedWork W2117916573 @default.
• W4379329566 hasRelatedWork W2158527017 @default.
• W4379329566 hasRelatedWork W2400032093 @default.
• W4379329566 hasRelatedWork W2413106834 @default.
• W4379329566 hasRelatedWork W2584535031 @default.
• W4379329566 hasRelatedWork W2763153490 @default.
• W4379329566 hasRelatedWork W3084168320 @default.
• W4379329566 hasRelatedWork W3097174646 @default.
• W4379329566 hasRelatedWork W3203327602 @default.
• W4379329566 hasVolume "41" @default.
• W4379329566 isParatext "false" @default.
• W4379329566 isRetracted "false" @default.
• W4379329566 workType "article" @default.